DOI: https://doi.org/10.22141/2306-2436.6.3.2017.123493

Ambroxol in comprehensive treatment of patients with acute respiratory diseases

O.K. Duda, V.O. Boyko, L.P. Kotsiubailo, A.I. Konoplianik

Abstract


The article presents data on optimization of pathogenetic therapy in patients with acute respiratory diseases with manifestations of tracheitis, bronchitis and complicated by community-acquired pneumonia in adults. The etiological structure of acute respiratory diseases and resistance to antibacterial preparations are described. The role of ambroxol hydrochloride in comprehensive treatment of patients with acute respiratory diseases with various complications from the respiratory system is shown. It has been established that the use of ambroxol hydrochloride positively affects the basic etiological process, reduces the time of hospital stay due to the rapid termination of bacterial excretion by the average of 3.8 ± 0.7 days in 75 % of patients (p = 0.001).


Keywords


ambroxol hydrochloride; acute respiratory diseases; productive cough; treatment; adults

Full Text:

PDF

References


Unified clinical protocol for primary care for adults and children. Acute respiratory infections. Order of the Ministry of Health of Ukraine. July 16, 2014, № 499.

Kramarev S.O. Approaches to antibacterial therapy of acute respiratory infections in children / Kramarev S.O., Yevtushenko V.V. // Actual infectology. — 2015. — № 1(6). — P. 7-12.

Feshchenko Yu.I. Pneumonia today: clinical variants, etiology and etiotropic therapy / Yu.I. Feshchenko // Treatment and diagnostics. — 2000. — № 2. — P. 18-24.

Simonova O.I., Gorinova Yu.V. Inhalation therapy with ambroxol solution (Lazolvan®): benefits, application specifics, effectiveness // RMJ. — 2014. — № 21. — Р. 1530.

Simonova O.I. Clinical effects of ambroxol hydrochloride (lasolvan®): what does the effectiveness of the drug depend on? // Pediatrics. — 2011. — № 5. — P. 128-133.

Beeh K.M., Beier J., Esperester A., Paul L.D. Antiinflammatory properties of ambroxol // Eur. J. Med. Res. — 2008. — Vol. 13(12). — P. 557-562.

Cataldi M., Sblendorio V., Leo A., Piazza O. Biofilm-dependent airway infections: A role for ambroxol? // Pulm. Pharmacol. Ther. — 2014. — Vol. 28 (2). — P. 98-108.

Malerba M., Ragnoli B. Ambroxol in the 21st Century: Pharmaceutical and clinical update // Expert Opin. Drug Metab. Toxicol. — 2008. — Vol. 4(8). — P. 1119-1129.

Huang J., Xu J., Tian L., Zhong L. A thioredoxin reductase and / or thioredoxin system-based mechanism for antioxidant effects of ambroxol // Biochimie. — 2014. — Vol. 97. — P. 92-103.

Zhang Z.Q., Wu Q.Q., Huang X.M., Lu H. Prevention of respiratory distress syndrome in preterm infants by antenatal ambroxol: a meta-analysis of randomized controlled trials // Am. J. Perinatol. — 2013. — Vol. 30(7). — P. 529-536.

Cunnigham F.M. et al. Effect of Ambroxol on mucociliary transport in the guinea pig // Br. J. Pharmacol. — 1983. — Vol. 80 (Suppl). — P. 693.

Eckert H., Lux M., Lachmann B. The role of alveolar macrophages in surfactant turnover. An experimental study on metabolite VIII of bromhexine (ambroxol) // Lung. — 1983. — Vol. 161. — P. 213-218.

Heath M.F., Jacobson W. The action of lung lysosomal phospholipases is dipalmitoyl phosphatidylcholine and its significance for the synthesis of pulmonary surfactant // Pediatr. Res. — 1980. — Vol. 14. — P. 254-258.

Bonnetti P. Ambroxol plus amoxicillin versus amoxicillin alone in various respiratory tract infections. Investig // Medica Internacional. — 1993. — Vol. 20. — P. 99-103.




Copyright (c) 2018 Health of Society

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019